D-0777-2021 Class II Terminated

Recalled by Granules USA, Inc. — Parsippany, NJ

FDA drug recall D-0777-2021 was initiated by Granules USA, Inc. on Aug 11, 2021 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Feb 16, 2023). Affected quantity: 11,450,000 tablets.

Recall details

Product Type
Drugs
Report Date
Sep 8, 2021
Initiation Date
Aug 11, 2021
Termination Date
Feb 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
11,450,000 tablets

Product description

Naproxen Sodum Tablets USP 220 mg, (Caplet), Manufactured by: Granules India Limited, Sy.No. 160/A, 161/E, 162, &174/A, Gagillapur Village, Dundigal-Gandimalsamma Monday, Medchai-Maikhajgir District - 500043, Telangana, INDIA. NDC 62207-762-36

Reason for recall

CGMP Deviations

Distribution pattern

NY

Code information

7620060a

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0777-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0777-2021. Report a data issue: hello@regdatalab.com.